NasdaqGS:QUREBiotechs
uniQure (QURE) Valuation Update After FDA Feedback Clouds AMT-130’s Current Path to a Biologics Filing
uniQure (NasdaqGS:QURE) just received final meeting minutes from the FDA on its AMT-130 gene therapy for Huntington's disease, and regulators signaled that current Phase I/II data likely will not anchor a Biologics License Application.
See our latest analysis for uniQure.
The cautious FDA feedback lands after a volatile stretch, with uniQure’s share price at $20.43, a 30 day share price return of negative 31.63 percent, a 90 day share price return of 44.28 percent, and a 1 year total...